BR112023025221A2 - Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos - Google Patents

Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos

Info

Publication number
BR112023025221A2
BR112023025221A2 BR112023025221A BR112023025221A BR112023025221A2 BR 112023025221 A2 BR112023025221 A2 BR 112023025221A2 BR 112023025221 A BR112023025221 A BR 112023025221A BR 112023025221 A BR112023025221 A BR 112023025221A BR 112023025221 A2 BR112023025221 A2 BR 112023025221A2
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
ppar
agonist compounds
ppar agonist
Prior art date
Application number
BR112023025221A
Other languages
English (en)
Inventor
George Mulligan
Marina Tanaka
Mototsugu Ito
Naotoshi Kanemitsu
Seiji Takae
Original Assignee
Astellas Pharma Inc
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Mitobridge Inc filed Critical Astellas Pharma Inc
Publication of BR112023025221A2 publication Critical patent/BR112023025221A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos. a presente invenção refere-se aos métodos de uso de um agonista de receptores delta ativados por proliferadores de peroxissoma (ppar¿) (por exemplo, composto (i) ou um sal farmaceuticamente aceitável do mesmo divulgado neste documento), por exemplo, para tratar pacientes que tem miopatias mitocondriais primárias (pmm). a presente divulgação também refere-se a uma composição farmacêutica compreendendo um agonista de receptores delta ativados por proliferadores de peroxissoma (ppar¿) e croscarmelose sódica.
BR112023025221A 2021-06-02 2022-06-02 Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos BR112023025221A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196013P 2021-06-02 2021-06-02
US202163196826P 2021-06-04 2021-06-04
PCT/US2022/031977 WO2022256540A1 (en) 2021-06-02 2022-06-02 Methods of use of ppar agonist compounds and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
BR112023025221A2 true BR112023025221A2 (pt) 2024-02-27

Family

ID=82358623

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023025221A BR112023025221A2 (pt) 2021-06-02 2022-06-02 Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos

Country Status (8)

Country Link
EP (1) EP4346807A1 (pt)
JP (1) JP2024521353A (pt)
KR (1) KR20240037940A (pt)
AU (1) AU2022286415A1 (pt)
BR (1) BR112023025221A2 (pt)
CA (1) CA3221429A1 (pt)
IL (1) IL308711A (pt)
WO (1) WO2022256540A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908695A1 (en) 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists
MA52098A (fr) 2015-10-07 2021-01-27 Mitobridge Inc Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
MY202008A (en) 2016-10-05 2024-03-28 Mitobridge Inc Crystalline and salt forms of ppar agonist compounds
TW202045152A (zh) * 2019-02-20 2020-12-16 美商雷內奧製藥股份有限公司 PPARẟ促效劑於治療粒線體性肌病之用途

Also Published As

Publication number Publication date
KR20240037940A (ko) 2024-03-22
JP2024521353A (ja) 2024-05-31
AU2022286415A1 (en) 2023-12-14
WO2022256540A1 (en) 2022-12-08
CA3221429A1 (en) 2022-12-08
IL308711A (en) 2024-01-01
EP4346807A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
BR112019025214A2 (pt) Composição farmacêutica sólida administrável por via oral, uso da composição farmacêutica, processo para a preparação de composições farmacêuticas, e, método de tratamento de um paciente que sofre de condições patológicas
BRPI0407618A (pt) derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
ZA202200519B (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
BR112022003514A2 (pt) Degradadores bifuncionais de brd9 e seus métodos de uso
BR112021026445A2 (pt) Composições e métodos para tratar distúrbios de cns
BR112021019007A2 (pt) Protacs que degradam o receptor de estrogênio
BR112023022050A2 (pt) Agonistas do receptor de orexina e usos destes
BR112018007947A2 (pt) uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash
BR112022008677A2 (pt) Terapia de combinação com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidina-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida
BRPI0607214B8 (pt) derivados de 2-(4-cianofenilamino)pirimidina inibidores de hiv, composição farmacêutica que os compreende e seus processos de preparação
CL2023000196A1 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
BR112021002565A8 (pt) Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto
MX2021002611A (es) Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo.
MX2023013683A (es) Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a).
WO2020128816A3 (en) Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
BR112023025221A2 (pt) Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos
BRPI0518823A2 (pt) compostos de triazol adequados para o tratamento de transtornos que respondam À modulaÇço do receptor d3 da dopamina
PH12021550258A1 (en) Cdk8/19 inhibitors
BR112022006381A2 (pt) Pró-fármacos de inibidores de mieloperoxidase
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
BR112021022752A2 (pt) Composições e métodos para potencializar o efeito músculo-esquelético de um ou mais aminoácidos anabólicos